Scale potential CorePharma operates 4 FDA- and DEA-registered facilities with an annual capacity of 5 billion dosage units, indicating strong manufacturing scale and opportunity for large or multi-SKU CDMO engagements, especially for clients seeking end-to-end development to commercial launch.

Diverse therapy focus As a full-spectrum CDMO serving diverse therapeutic categories, CorePharma can accommodate partners across multiple pipelines, enabling cross-sell opportunities for companies with broad or evolving development needs.

Global compliance Regulatory excellence and established facilities reduce risk for clients needing robust quality, regulatory alignment, and rapid scale-up, making CorePharma an attractive option for accelerated timelines and compliant production.

Cyber risk alert Recent ransomware activity highlights the importance of secure operations; engaging CorePharma with a focus on cybersecurity readiness and business continuity may be a differentiator for risk-sensitive partners and could lead to complementary security services conversations.

Leadership continuity Strategic leadership transitions in 2018 and ongoing CEO/board involvement suggest stable governance and forward-looking strategy, supporting enterprise partnerships that require long-term commitment and consistency in program ownership.